Steven Cohen Taysha Gene Therapies, Inc. Transaction History

Point72 Asset Management, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.43 - $3.25 $2.25 Million - $5.12 Million	-1,574,768 Reduced 58.59%	1,113,232 $3.19 Million
Q4 2023 Feb 14, 2024	BUY	$1.33 - $2.88 $2.33 Million - $5.04 Million	1,751,450 Added 187.01%	2,688,000 $4.76 Million
Q3 2023 Nov 14, 2023	BUY	$0.63 - $3.66 $590,026 - $3.43 Million	936,550 New	936,550 $2.96 Million
Q1 2021 May 17, 2021	SELL	$20.3 - $31.75 $271,329 - $424,370	-13,366 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$19.14 - $28.13 $3.57 Million - $5.25 Million	-186,634 Reduced 93.32%	13,366 $355,000
Q3 2020 Nov 16, 2020	BUY	$22.4 - $24.47 $4.48 Million - $4.89 Million	200,000 New	200,000 $4.48 Million

119

136M

25.9K

24K

Ticker TSHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,359,500
Market Cap $119M
Description
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.